CONDITIONALLY REPLICATING CYTOMEGALOVIRUS AS VACCINE AGAINST CMV Russian patent published in 2017 - IPC A61K39/245 C12N15/38 C07K14/45 C07K19/00 C07H21/04 

FIELD: biotechnology.

SUBSTANCE: present invention relates to biotechnology. Conditionally defective replication of Cytomegalovirus (CMV) and compositions containing it are disclosed for use as vaccine, method of production and use of said CMV in preparing drug and in medicine and application of specified composition for inducing immune response against CMV in patient. Proposed CMV conditionally defective by replication contains pentamerous gH-complex including UL128, UL130, UL131, gH and gL, and two nucleic acid coding fused protein. First fused protein consists of IE1/2 and destabilizing protein, second fused protein is from UL51 and destabilizing protein. Destabilizing protein is FK506-binding protein (FKBP) or its derivatives with amino acid substitutes F36V and L106P. Proposed CMV has restored expression of gH-complex by mutation correction UL131 and it has no wild type IE1/2 and UL51.

EFFECT: proposed CMV can be used in medicine as component of vaccines based on attenuated strains of CMV, generating neutralizing antibody and causing T-cell immune responses.

19 cl, 39 dwg, 2 tbl, 7 ex